<DOC>
	<DOCNO>NCT01361061</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) one tumor rise incidence worldwide . The aim trial improve detection early HCC nodule liver . At moment screen HCC patient liver cirrhosis perform ultrasound measurement alpha- fetoprotein ( AFP ) . In trail tumor marker AFP- L3 ( subfraction AFP ) Des-y- carboxyprothromib ( DCP ) measure addition order receive information course marker detection HCC nodule .</brief_summary>
	<brief_title>AFP - L3 % DCP Screening Marker Hepatocellular Carcinoma Patients With Cirrhosis Liver</brief_title>
	<detailed_description>The incidence hepatocellular carcinoma ( HCC ) rise worldwide . Usually arise patient liver cirrhosis . That 's reason patient screen every six month ultrasound performance measurement alpha-fetoprotein ( AFP ) order detect grow tumor cirrhotic liver possible curative treatment may possible . In last year new tumor marker identify Des-y- carboxyprothromib ( DCP ) AFP - L3 . AFP total consist three different glycoforms ( AFP - L1 , AFP - L2 AFP - L3 ) different bind affinity lens culinaris agglutinin ( LCA ) . Among glycoprotein AFP - L3 high bind affinity LCA occur predominantly patient HCC whereas subtypes find rather patient benign disease liver chronic hepatitis cirrhosis liver . Some study show high serum level AFP - L3 associate reduced function liver , low differentiation high malignancy HCC . Furthermore HCC - nodule diameter small 2 cm could detect rise AFP - L3 serum level . Moreover significant difference AFP - L3 serum level patient cirrhosis liver without HCC tumor . In conclusion rise AFP - L3 serum level could indicate newly develop tumour . Des-y- carboxyprothromib ( DCP ) , first described 1984 Liebmann et al . another tumor marker HCC . In contrast AFP elevate patient benign disease liver . This could interest fact concern screen patient liver cirrhosis . In examination diagnostic value AFP , AFP - L3 % DCP evaluate . An important aim prospective clinical trial define specificity serum marker alone combination . If patient develops primary liver tumor course tumor marker development tumor analyse . Furthermore examined parameter lead false positive DCP value ( especially chronic kidney disease application phenprocoumon ) . During 2 year approximately 150 patient center approve cirrhosis liver enrol . According normal screening procedure serum sample collect measurement AFP , AFP- L3 % DCP . If suspect tumor nodule detect , confirmation diagnosis `` HCC '' accord AASLD- criterion need . These patient exclude examination treat accord actual guideline . The aim improve early diagnosis HCC curative treatment opportunity do .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>age 18 80 cirrhosis liver confirm ultrasound imaging technique ( MRI , CT ) biopsy time enrollment : HCC suspect lesion detectable liver liver tumor metastasis tumor unknown origin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>liver cirrhosis</keyword>
	<keyword>screen</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>liver cancer marker : AFP , AFP-L3 % DCP</keyword>
</DOC>